Survodutide Peptide (BI 456906) – High Purity Research Compound
Introduction to Survodutide Peptide
Survodutide, also identified in scientific literature as BI 456906, is a cutting-edge dual GLP-1 and Glucagon receptor agonist currently under active investigation for its unique and potent metabolic effects. Unlike GLP-1–only analogs, which primarily focus on appetite suppression, Survodutide is specifically engineered to additionally promote energy expenditure through targeted glucagon activation.
At Peptides Skin, Survodutide is offered as a high-purity lyophilized powder, meticulously prepared for strict in vitro and controlled laboratory research settings.
Mechanism of Action: Dual GLP-1 / Glucagon Agonism
The profound scientific interest in Survodutide stems from its distinctive dual-target receptor profile, offering a comprehensive approach to metabolic regulation:
- GLP-1 Receptor Activation: This pathway is well-known for its role in appetite regulation, slowing gastric emptying, and modulating glucoregulatory processes, contributing to improved metabolic control.
- Glucagon Receptor Activation (GCGR): Crucially, glucagon activation increases resting metabolic rate and actively promotes lipolysis, facilitating the mobilization and utilization of fatty acids for energy.
This synergistic dual mechanism provides a powerful tool for metabolic research, simultaneously reducing caloric intake and significantly enhancing energy expenditure.
Key Research Applications of Survodutide
1. Metabolic Research & Energy Expenditure
Phase 2 clinical findings, reported by Boehringer Ingelheim and Zealand Pharma, indicate significant reductions in body weight and adiposity in various experimental models. Survodutide provides researchers with a unique opportunity to directly compare the efficacy and mechanisms of dual agonism versus mono-agonism in the complex pathways of weight regulation and energy balance.
2. MASH / Liver Health Studies
Survodutide is a focal point in studies investigating Metabolic Dysfunction-Associated Steatohepatitis (MASH). Evidence suggests that glucagon activation directly contributes to reducing hepatic fat accumulation, making this peptide invaluable for research into liver fibrosis, steatosis, and broader liver health.
Survodutide vs. Semaglutide vs. Retatrutide: A Comparative Overview
| Peptide | Receptor Targets | Primary Research Focus |
|---|---|---|
| Survodutide | GLP-1 + Glucagon | Energy Expenditure, Obesity, MASH |
| Semaglutide | GLP-1 Only | Satiety, Glycemic Regulation |
| Retatrutide | GLP-1 + GIP + Glucagon | Triple Agonist – Maximal Metabolic Impact |
Technical Specifications
- Chemical Name: Survodutide (BI 456906)
- Type: Dual GLP-1/Glucagon Analog
- Purity: ≥ 99% (HPLC Verified)
- Form: Sterile lyophilized powder
- Solubility: Water, Saline, Bacteriostatic Water
- Source: Synthetic peptide
Storage & Handling Guidelines
Proper storage is essential to maintain Survodutide’s integrity and purity:
- Lyophilized Powder: Store at −20 °C or below for optimal stability (typically stable for up to 24 months).
- Reconstituted Solution: Refrigerate at 4 °C and use within 2–3 weeks to ensure potency.
- Avoid: Repeated freeze–thaw cycles, direct heat exposure, and high humidity, which can degrade the compound.
Safety & Research Disclaimer
For Laboratory Research Only — Not for Human Use.
- This product is not intended for injection, therapeutic, or diagnostic use.
- Always use appropriate Personal Protective Equipment (PPE) when handling this compound.
- Refer to the Material Safety Data Sheet (MSDS) for comprehensive safety guidance and handling protocols.
Why Choose Peptides Skin for Your Research?
- Third-Party Tested: Every batch undergoes rigorous verification via HPLC and Mass Spectrometry to guarantee purity and authenticity.
- B2B Reliability: Consistent stock availability and research-grade purity to support uninterrupted projects.
- Temperature-Controlled Shipping: Specialized logistics maintain optimal temperatures, safeguarding molecular stability from our facility to your lab.
Frequently Asked Questions About Survodutide
What is the difference between Survodutide and Tirzepatide?
Survodutide targets GLP-1 and Glucagon receptors, with its primary research focus on enhancing energy expenditure. In contrast, Tirzepatide targets GLP-1 and GIP receptors, primarily emphasizing insulin sensitivity and appetite regulation.
What benefits are observed in Survodutide research?
Research models consistently show significant reductions in body weight, liver fat, and improvements in metabolic dysfunction. These benefits are primarily attributed to the combined effects of appetite suppression and glucagon-driven increases in energy expenditure.
Is Survodutide similar to Semaglutide?
No. Semaglutide is a GLP-1 mono-agonist, meaning it activates only the GLP-1 receptor. Survodutide, however, activates both GLP-1 and Glucagon receptors, providing a distinct dual metabolic effect that includes enhanced energy expenditure.
Can Survodutide be purchased for personal use?
No. Survodutide from Peptides Skin is strictly designated for laboratory research purposes and is not approved for personal consumption, medical treatment, or any clinical use.